이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Beijing Tong Ren Tang Chinese Medicine 미래 성장

Future 기준 확인 3/6

Beijing Tong Ren Tang Chinese Medicine (는) 각각 연간 15.2% 및 13.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18% 로 예상됩니다.

주요 정보

15.2%

수익 성장률

17.5%

EPS 성장률

Pharmaceuticals 수익 성장	10.7%
매출 성장률	13.6%
향후 자기자본 수익률	18.0%
애널리스트 커버리지	Low
마지막 업데이트	19 Mar 2024

최근 미래 성장 업데이트

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23

수익 및 매출 성장 예측

SEHK:3613 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2,328	858	N/A	N/A	1
12/31/2025	1,988	758	N/A	716	2
12/31/2024	1,735	652	N/A	748	2
12/31/2023	1,525	540	439	461	N/A
9/30/2023	1,721	619	552	584	N/A
6/30/2023	1,918	697	665	706	N/A
3/31/2023	1,824	672	587	627	N/A
12/31/2022	1,731	646	509	547	N/A
9/30/2022	1,605	601	636	665	N/A
6/30/2022	1,478	555	763	782	N/A
3/31/2022	1,517	582	758	779	N/A
12/31/2021	1,556	608	754	777	N/A
9/30/2021	1,504	595	575	596	N/A
6/30/2021	1,452	583	397	414	N/A
3/31/2021	1,384	563	250	265	N/A
12/31/2020	1,315	542	103	116	N/A
9/30/2020	1,246	483	198	213	N/A
6/30/2020	1,178	424	294	310	N/A
3/31/2020	1,305	490	414	430	N/A
12/31/2019	1,433	556	534	551	N/A
9/30/2019	1,505	594	553	568	N/A
6/30/2019	1,577	632	572	585	N/A
3/31/2019	1,546	601	N/A	N/A	N/A
12/31/2018	1,514	581	524	578	N/A
9/30/2018	1,466	552	N/A	N/A	N/A
6/30/2018	1,402	540	447	507	N/A
3/31/2018	1,330	516	N/A	N/A	N/A
12/31/2017	1,266	490	435	469	N/A
9/30/2017	1,212	469	N/A	N/A	N/A
6/30/2017	1,166	449	N/A	465	N/A
3/31/2017	1,134	444	N/A	N/A	N/A
12/31/2016	1,084	420	N/A	468	N/A
9/30/2016	1,063	431	N/A	N/A	N/A
6/30/2016	1,028	410	N/A	415	N/A
3/31/2016	1,002	380	N/A	N/A	N/A
12/31/2015	970	354	N/A	354	N/A
9/30/2015	939	337	N/A	N/A	N/A
6/30/2015	881	320	N/A	316	N/A
3/31/2015	834	304	N/A	N/A	N/A
12/31/2014	761	287	N/A	245	N/A
9/30/2014	733	286	N/A	N/A	N/A
6/30/2014	699	267	N/A	202	N/A
3/31/2014	652	249	N/A	N/A	N/A
12/31/2013	614	220	N/A	143	N/A
9/30/2013	530	176	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 3613 의 연간 예상 수익 증가율( 15.2% )이 saving rate( 2.2% 보다 높습니다. ).

수익 vs 시장: 3613 의 연간 수익( 15.2% ) Hong Kong 시장( 11.7% 보다 빠르게 성장할 것으로 예상됩니다. 11.7% 연간).

고성장 수익: 3613 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 3613 의 수익(연간 13.6% ) Hong Kong 시장( 7.8% 보다 빠르게 성장할 것으로 예상됩니다. 7.8% 연간).

고성장 수익: 3613 의 수익(연간 13.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 3613 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18 %).

Beijing Tong Ren Tang Chinese Medicine 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 14% to HK$14.93

Price target increased by 8.0% to HK$14.66

Price target decreased to HK$13.57

Price target lowered to HK$12.45

Analysts lower EPS estimates to HK$0.60

Price target lowered to HK$13.18

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended December 31, 2023

Now 22% overvalued after recent price rise

Upcoming dividend of HK$0.33 per share

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Wang Chi as an Executive Director and a Member of the Competition Executive Committee

Now 21% overvalued after recent price rise

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces CEO Changes

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 31, 2024

New minor risk - Financial data availability

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Price target decreased by 14% to HK$14.93

Investor sentiment deteriorates as stock falls 16%

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2023 Results on Mar 31, 2024

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Gu Hai Ou as Executive Director, Chairman of Board and Authorised Representative

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2023 Results on Oct 31, 2023

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Resignation of Lin Man as Executive Director, Chief Operating Officer, Member of Competition Executive Committee

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Retirement of Ding Yong Ling as Executive Director and Chairman of the Board

First half 2023 earnings released: EPS: HK$0.32 (vs HK$0.26 in 1H 2022)

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2023 Results on Aug 10, 2023

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.33 per share at 2.1% yield

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Price target increased by 8.0% to HK$14.66

Less than half of directors are independent

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Nine Months, 2022 Results on Oct 31, 2022

Upcoming dividend of HK$0.25 per share

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Special Interim Dividend, Payable on 21 October 2022

High number of new directors

COO & Executive Director recently bought HK$183k worth of stock

Price target decreased to HK$13.57

First half 2022 earnings released

Beijing Tong Ren Tang Chinese Medicine Company Limited Appoints Feng Li as Executive Director

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.28 per share

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited Proposes Final Dividend for the Year Ended 31 December 2021

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2021 Results on Mar 07, 2022

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$178k worth of stock

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

First half 2021 earnings released: EPS HK$0.32 (vs HK$0.27 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Beijing Tong Ren Tang Chinese Medicine Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment improved over the past week

Upcoming dividend of HK$0.24 per share

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Beijing Tong Ren Tang Chinese Medicine Company Limited, Annual General Meeting, May 28, 2021

Beijing Tong Ren Tang Chinese Medicine Company Limited Announces Appointment of Chen Fei as Executive Director

CEO & Executive Director Huan Ping Zhang has left the company

Full year 2020 earnings released: EPS HK$0.65 (vs HK$0.66 in FY 2019)

Revenue and earnings beat expectations

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Beijing Tong Ren Tang Chinese Medicine Company Limited to Report Fiscal Year 2020 Results on Mar 11, 2021

Investor sentiment improved over the past week

New 90-day high: HK$9.58

Beijing Tong Ren Tang Chinese Medicine Company Limited (SEHK:3613) entered into the Sale and Purchase Agreement to acquire 40% stake in Beijing Tong Ren Tang WM Dianorm Biotech Co., Limited from WM Dianorm Biotech Co., Limited for RMB 33.1 million.